$64.9 Million is the total value of Knoll Capital Management, LLC's 26 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 133.3% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ALDX | Buy | Aldeyra Therapeutics Inc | $20,526,898 | +51.4% | 2,067,160 | +6.1% | 31.64% | +3.4% |
AVDL | New | Avadel Pharmaceuticals Plccall | $4,580,000 | – | 500,000 | +100.0% | 7.06% | – |
VRNA | Buy | Verona Pharmasponsored ads | $4,016,000 | +61.1% | 200,000 | +109.7% | 6.19% | +10.0% |
APLT | Buy | Applied Therapeutics Inc | $2,797,950 | +50.3% | 3,450,000 | +40.8% | 4.31% | +2.6% |
OCUL | New | Ocular Therapeutix Inc. | $1,504,000 | – | 200,000 | +100.0% | 2.32% | – |
OR | Buy | OSISKO GOLD ROYALTIES LTD | $1,272,000 | +109.3% | 400,000 | +70.2% | 1.96% | +43.0% |
New | Omega Therapeutics Inc. | $1,043,250 | – | 173,010 | +100.0% | 1.61% | – | |
SILV | New | Silvercrest Metals Inc CAD | $1,043,614 | – | 170,000 | +100.0% | 1.61% | – |
SA | Buy | SEABRIDGE GOLD INC | $1,036,000 | +100.9% | 80,000 | +95.1% | 1.60% | +37.2% |
FNV | New | Franco Nev Corp CAD | $1,020,600 | – | 7,000 | +100.0% | 1.57% | – |
NOC | New | Northrop Grumman Corp | $999,623 | – | 2,165 | +100.0% | 1.54% | – |
OCUL | New | Ocular Therapeutix Inc.call | $504,866 | – | 95,800 | +100.0% | 0.78% | – |
OCUP | New | Ocuphire Pharma Inc. | $375,000 | – | 100,000 | +100.0% | 0.58% | – |
HOOK | Buy | HOOKIPA PHARMA | $220,800 | +445.2% | 300,000 | +500.0% | 0.34% | +273.6% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Aldeyra Therapeutics Inc | 35 | Q3 2023 | 31.6% |
Corbus Pharmaceuticals HLDGS | 30 | Q3 2022 | 46.5% |
Abeona Therapeutics Inc | 30 | Q3 2022 | 34.8% |
Biohaven Pharmactl Hldg Co L | 26 | Q3 2023 | 79.6% |
Entera Bio Ltd | 22 | Q3 2023 | 7.8% |
Ampio Pharmaceuticals Inc. | 21 | Q2 2018 | 11.0% |
Soligenix Inc. | 20 | Q3 2022 | 1.7% |
Eiger Biopharmaceuticals Inc | 19 | Q3 2022 | 5.8% |
Applied Therapeutics Inc | 18 | Q3 2023 | 19.7% |
Alcobra Ltd | 18 | Q3 2017 | 6.5% |
View Knoll Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
HOOKIPA Pharma Inc. | June 20, 2023 | 5,517,385 | 6.8% |
Applied Therapeutics Inc. | January 23, 2023 | 3,450,000 | 7.2% |
Orgenesis Inc. | August 14, 2020 | 1,316,364 | 5.9% |
Corbus Pharmaceuticals Holdings, Inc. | February 14, 2020 | 5,045,870 | 7.1% |
ABEONA THERAPEUTICS INC. | February 14, 2018 | 2,359,767 | 5.0% |
SOLIGENIX, INC. | November 13, 2017 | 870,000 | 9.9% |
ABEONA THERAPEUTICS INC. | February 14, 2017 | 2,359,767 | 5.9% |
ALCOBRA LTD. | February 14, 2017 | 1,205,498 | 4.4% |
Ampio Pharmaceuticals, Inc. | February 14, 2017 | 2,738,322 | 4.8% |
RITTER PHARMACEUTICALS INC | February 14, 2017 | 952,434 | 8.2% |
View Knoll Capital Management, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
SC 13G/A | 2024-01-16 |
13F-HR | 2023-11-14 |
SC 13G | 2023-10-04 |
13F-HR | 2023-08-15 |
SC 13G | 2023-06-20 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-14 |
SC 13G | 2023-01-23 |
13F-HR | 2022-11-14 |
View Knoll Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.